-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 3, the official website of the State Food and Drug Administration showed that the 3-type generic drug dexmedetomidine hydrochloride injection of Chia Tai Qingjiang was approved for production and was deemed to have been reviewed
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 4 billion yuan in 2020, a year-on-year increase of 10.
61%
.
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 4 billion yuan in 2020, a year-on-year increase of 10.
61%
.
Source: State Food and Drug Administration official website
Dexmedetomidine hydrochloride belongs to the α2-renal/upper/adrenal/hormone receptor agonist with sedative, analgesic, anxiolytic and other effects.
It is clinically used for tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia.
Calm down
.
It is clinically used for tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia.
Calm down
.
At present, 16 domestic companies have the production approval for dexmedetomidine hydrochloride injection.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers and township health centers in China in 2020 (referred to as China Public Medical Center for short).
Institutions) terminal sales scale was close to 4 billion yuan, an increase of 10.
61% year-on-year
.
Relying on the exclusive bid in 4+7 and expanded centralized procurement, Yangzijiang's products have been in rapid volume in recent years, and currently has an exclusive market share of more than 90%
.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers and township health centers in China in 2020 (referred to as China Public Medical Center for short).
Institutions) terminal sales scale was close to 4 billion yuan, an increase of 10.
61% year-on-year
.
Relying on the exclusive bid in 4+7 and expanded centralized procurement, Yangzijiang's products have been in rapid volume in recent years, and currently has an exclusive market share of more than 90%
.
Partial review of dexmedetomidine hydrochloride injection
Source: Minet Consistency Evaluation Database
Before CP Qingjiang, the dexmedetomidine hydrochloride injection of 14 domestic companies has passed or is deemed to pass the consistency evaluation, including Yangzijiang, Hengrui, Beite, Enhua, Nanjing CP Tianqing, etc.
; Products from nearly 10 companies including General Pharmaceutical, Hebei Renhe Yikang, Chia Tai Fenghai, and Minsheng Pharmaceutical have submitted supplementary applications for consistency evaluation or reported production under new classifications, which are currently under review and approval
.
; Products from nearly 10 companies including General Pharmaceutical, Hebei Renhe Yikang, Chia Tai Fenghai, and Minsheng Pharmaceutical have submitted supplementary applications for consistency evaluation or reported production under new classifications, which are currently under review and approval
.
Zhengda Qingjiang Review Status
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Including dexmedetomidine hydrochloride injection, at present, 5 varieties of CP Qingjiang have passed or deemed to pass the consistency evaluation, of which glucosamine hydrochloride tablet is the exclusive one
.
.
On March 3, the official website of the State Food and Drug Administration showed that the 3-type generic drug dexmedetomidine hydrochloride injection of Chia Tai Qingjiang was approved for production and was deemed to have been reviewed
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 4 billion yuan in 2020, a year-on-year increase of 10.
61%
.
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 4 billion yuan in 2020, a year-on-year increase of 10.
61%
.
Source: State Food and Drug Administration official website
Dexmedetomidine hydrochloride belongs to the α2-renal/upper/adrenal/hormone receptor agonist with sedative, analgesic, anxiolytic and other effects.
It is clinically used for tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia.
Calm down
.
It is clinically used for tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia.
Calm down
.
At present, 16 domestic companies have the production approval for dexmedetomidine hydrochloride injection.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers and township health centers in China in 2020 (referred to as China Public Medical Center for short).
Institutions) terminal sales scale was close to 4 billion yuan, an increase of 10.
61% year-on-year
.
Relying on the exclusive bid in 4+7 and expanded centralized procurement, Yangzijiang's products have been in rapid volume in recent years, and currently has an exclusive market share of more than 90%
.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers and township health centers in China in 2020 (referred to as China Public Medical Center for short).
Institutions) terminal sales scale was close to 4 billion yuan, an increase of 10.
61% year-on-year
.
Relying on the exclusive bid in 4+7 and expanded centralized procurement, Yangzijiang's products have been in rapid volume in recent years, and currently has an exclusive market share of more than 90%
.
Partial review of dexmedetomidine hydrochloride injection
Source: Minet Consistency Evaluation Database
Before CP Qingjiang, the dexmedetomidine hydrochloride injection of 14 domestic companies has passed or is deemed to pass the consistency evaluation, including Yangzijiang, Hengrui, Beite, Enhua, Nanjing CP Tianqing, etc.
; Products from nearly 10 companies including General Pharmaceutical, Hebei Renhe Yikang, Chia Tai Fenghai, and Minsheng Pharmaceutical have submitted supplementary applications for consistency evaluation or reported production under new classifications, which are currently under review and approval
.
; Products from nearly 10 companies including General Pharmaceutical, Hebei Renhe Yikang, Chia Tai Fenghai, and Minsheng Pharmaceutical have submitted supplementary applications for consistency evaluation or reported production under new classifications, which are currently under review and approval
.
Zhengda Qingjiang Review Status
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Including dexmedetomidine hydrochloride injection, at present, 5 varieties of CP Qingjiang have passed or deemed to pass the consistency evaluation, of which glucosamine hydrochloride tablet is the exclusive one
.
.
On March 3, the official website of the State Food and Drug Administration showed that the 3-type generic drug dexmedetomidine hydrochloride injection of Chia Tai Qingjiang was approved for production and was deemed to have been reviewed
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 4 billion yuan in 2020, a year-on-year increase of 10.
61%
.
.
According to data from Minet.
com, the sales of this product in China's public medical institutions will be close to 4 billion yuan in 2020, a year-on-year increase of 10.
61%
.
Source: State Food and Drug Administration official website
Dexmedetomidine hydrochloride belongs to the α2-renal/upper/adrenal/hormone receptor agonist with sedative, analgesic, anxiolytic and other effects.
It is clinically used for tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia.
Calm down
.
It is clinically used for tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia.
Calm down
.
At present, 16 domestic companies have the production approval for dexmedetomidine hydrochloride injection.
According to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers and township health centers in China in 2020 (referred to as China Public Medical Center for short).
Institutions) terminal sales scale was close to 4 billion yuan, an increase of 10.
61% year-on-year
.
Relying on the exclusive bid in 4+7 and expanded centralized procurement, Yangzijiang's products have been in rapid volume in recent years, and currently has an exclusive market share of more than 90%
.
Enterprise Enterprise Enterprise Hospital Hospital HospitalAccording to Minet.
com data, the product will be used in urban public hospitals , county-level public hospitals, urban community centers and township health centers in China in 2020 (referred to as China Public Medical Center for short).
Institutions) terminal sales scale was close to 4 billion yuan, an increase of 10.
61% year-on-year
.
Relying on the exclusive bid in 4+7 and expanded centralized procurement, Yangzijiang's products have been in rapid volume in recent years, and currently has an exclusive market share of more than 90%
.
Partial review of dexmedetomidine hydrochloride injection
Source: Minet Consistency Evaluation Database
Before CP Qingjiang, the dexmedetomidine hydrochloride injection of 14 domestic companies has passed or is deemed to pass the consistency evaluation, including Yangzijiang, Hengrui, Beite, Enhua, Nanjing CP Tianqing, etc.
; Products from nearly 10 companies including General Pharmaceutical, Hebei Renhe Yikang, Chia Tai Fenghai, and Minsheng Pharmaceutical have submitted supplementary applications for consistency evaluation or reported production under new classifications, which are currently under review and approval
.
; Products from nearly 10 companies including General Pharmaceutical, Hebei Renhe Yikang, Chia Tai Fenghai, and Minsheng Pharmaceutical have submitted supplementary applications for consistency evaluation or reported production under new classifications, which are currently under review and approval
.
Zhengda Qingjiang Review Status
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Including dexmedetomidine hydrochloride injection, at present, 5 varieties of CP Qingjiang have passed or deemed to pass the consistency evaluation, of which glucosamine hydrochloride tablet is the exclusive one
.
.
